Gapping up
In reaction to strong earnings/guidance: RNA +21.3%, FF +21.2%, ATEC +10.6%, MBT +3.1%, HTZ +2.3%, WPCS +1.9%, NVGS +1.6%, ACFN +1.4%, KYTH +0.7%, .
M&A news: NVS +0.5% (in discussions to purchase Gamida-Cell for up to $600 mln, according to reports).
Other news: ADXS +9.6% (receives patent in Japan for ADXS-HPV for the treatment of cervical cancer), OCLS +6.5% (Continued strength; move comes ahead of expected IPO of subsidiary Ruthigen), LOCM +4.1% (ticking higher following strength seen yesterday afternoon), YOD +3.8% (still checking), YNDX +3.3% (has purchased Tel Aviv's KitLocate location service technology, according to reports), PLUG +2.8% (cont volatility), KNDI +2.8% (cont strength), JASO +2.2% (cont strength), CBI +1.5% (co and Chiyoda announced their joint venture was awarded a contract for LNG liquefaction and export facilities), GTAT +1.2% (still checking), BIIB +1% (announces the FDA has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application for marketing approval of PLEGRIDY by three months).
Analyst comments:AMZN +2.91% (target raised to $455 at Oppenheimer), ICPT +1.8% (target raised to $500 at Needham), PVH +1.2% (initiated with an Overweight at Barclays), KATE +1.0% (initiated with an Overweight at Barclays), QGEN +0.9% (upgraded to Buy from Hold at Berenberg), HPQ +0.6% (upgraded to Overweight from Equal Weight at Barclays)